Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-25-000339
Filing Date
2025-01-02
Accepted
2025-01-02 16:28:57
Documents
2
Period of Report
2025-01-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm251653-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm251653-1_3seq1.xml 3 1624
2 EXHIBIT 24.1 tm251653d1_ex24-1.htm EX-24.1 7327
  Complete submission text file 0001104659-25-000339.txt   10623
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Issuer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O BAUDAX BIO, INC. 490 LAPP ROAD MALVERN PA 19355
Business Address
McAndrew Natalie (Reporting) CIK: 0001996811 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36296 | Film No.: 25502435